Clinical Trial Update: Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. [Phase 3]

View source ↗

Summary

A Phase 3 trial is comparing radiotherapy to everolimus for somatostatin receptor-positive neuroendocrine tumors of the lung and thymus, and is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Neuroendocrine Tumor
• Neuroendocrine Tumor
• Thymic Neuroendocrine Tumor

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm | Phase 3 | Status: RECRUITING